Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
주식 순위 #16450
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
주가
$4.64
마지막 동기화: 2022-09-12
시가총액
$293.43M
변동 (1일)
0.87%
변동 (1년)
0.00%
국가
US
거래 Adagio Therapeutics, Inc. (ADGI)

카테고리

Adagio Therapeutics, Inc. (ADGI)의 주식 분할 이력
Adagio Therapeutics, Inc. 주식 (심볼: ADGI)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Sep 02, 2026에 발생했습니다.
Sep 02, 2026 이전에 매수한 ADGI 주식 1주는 현재 0주의 ADGI 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH